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Methods: Works studying the association between
polymorphisms of rs12979860 or rs8099917 and the impact
on HCV treatment were retrieved in PubMed. After
evaluated independently by two researchers, data on
the distribution of patients reaching sustained virological
response (SVR) in different genotypes of the qualiﬁed studies
was abstracted and the summary ORs were calculated using
the relevant effect model of meta-analysis based on the
heterogeneity results in Stata 10.0 software.
Results: Twenty three studies that met the inclusion
criteria were included in the analysis, of which 9 were
on rs12979860, 8 on rs8099917 and 6 on both. Comparing
to subjects with the rs12979860 CT/TT genotype, HCV
infected patients carrying the CC genotype were more
likely to reach SVR after the PegIFN-RVB therapy (OR=3.18,
95%CI: 2.33 4.35). A similar result was observed in subjects
carrying rs8099917 TT genotype comparing to TG/GG
(OR=2.37, 95%CI: 1.73 3.23). As to the subgroup analysis,
those positive results above could only be observed in
the HCV genotype 1 group, but not in subjects infecting
HCV genotype non-1. The publication bias analysis had no
statistically signiﬁcant results.
Conclusion: rs12979860 and rs8099917 were involved in
the effects of HCV treatment with PegIFN-RVB, but this
impact could only be observed in relatively difﬁcult-to-treat
genotype 1 subjects.
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Thyroid dysfunction can be affected as a complication of
interferon therapy due to HCV infection. The aims of the
present study were to investigate the effect of interferon
therapy on the thyroid function on Egyptian patients with
HCV infection.
The study includes 60 HCV infected patients with normal
baseline levels of TSH. The patients receive a subcutaneous
pegylated interferon alfa-2b weekly in addition to oral
ribavirin (1000 1200mg/d). The patients were suspected
to complete history and clinical examination, with special
emphasis to hepatic and thyroid disorders. Before the start
of interferon therapy, serum TSH, thyroglobulin-Ab (TG-Ab)
and antiperooxidase antibodies (TPO-Ab) were measured.
Three months after interferon therapy serum levels of TSH
were performed to all patients, patients with abnormal TSH
were suspected to the measurements of FT3, FT4, TPO-Ab,
TG-Ab and thyroid stimulating immunoglobulin levels (TSI).
After 3 months of interferon therapy, 48 patients (80%)
had normal TSH and 12 patients (20%) had abnormal
TSH. Out of 12 patients had abnormal TSH, 10 patients
(16.6%) had high serum levels of TSH (hypothyroidisms),
while the remaining 2 patients (3.4%) had low serum
levels of TSH (hyperthyroidism). Out of 10 patients with
hypothyroidism, 6 patients (10%) had overt hypothyroidism
and 4 patients (6.6%) had subclinical hypothyroidism. All
patients with abnormal TSH had a signiﬁcant higher levels
of TG-Ab, TPO-Ab and STI. Out of two patients with
hyperthyroidism, one patient presented by clinical pictures
of overt hyperthyroidism, while the other patient presented
by subclinical hyperthyroidism.
In conclusion, the incidence of thyroid dysfunction during
pegylated interferon therapy in patients with HCV is 20%;
hypothyroids was more common than hyperthyroidism. The
patients most at risk for thyroid dysfunctions are people
with preexisting TPO-Abs. Patients with HCV infection
under pegylated interferon and ribavirin therapy should
be screened for thyroid dysfunction before and during
treatment.
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Introduction: CLD is one of the most common health
problems in Egypt due to the prevalence of bilharaiasis
as well as viral hepatitis. The way in which the family copes
with and adapts to chronic illness of one of its members has
a strong impact on the physical and psychosocial well-being
of all members and on the shape and duration of the clinical
course of the illness itself. The family doctor therefore
should be able to evaluate the families’ adaptation to
illness and to promote successful coping strategies where
necessary. The aim of this study is to improve family
function of patients with CLD through detection of family
dysfunction. The detection of family function is the ﬁrst
step in this regard.
Methodology: This study was cross sectional descriptive
study carried in communicable disease and research center
in Suez, its target population was adult patients of
both sexes with CLD. Total number of the sample was
233 patients. Each patient was subjected to the following:
1) Personal, social, geographic assessment.2) History and
physical examination. 3) Biochemical testing for Liver
function evaluation. The Assessment of family function was
done by using (FACESII).
Results: Current study showed that regarding to cohesion,
it was found that 70.4% of patients were balanced while
29.6% were extreme. Regarding to adaptability 66.1% were
balanced, while 33.9% were extreme. It found that 53.6% of
the patients were dysfunction families (mid range, extreme
family function), while 46.6% were balanced (function
families).
Conclusion: The present study concluded that, family
dysfunction is a considerable problem among patient with
CLD. It was no signiﬁcantly associated with almost all socio-
demographic except age of the patient, there were also
no signiﬁcantly associated with severity of CLD, number of
Symptoms and sign of CLD except gynecomastia (for males)
and abdominal swelling.
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Background and Objective: To explore the curative effect
of Transmetil in the treatment for patients with with
depressed emotion and Chronic liver failure in hepatitis B.
Methods: All 49 patients with Chronic liver failure in
hepatitis B were randomly divide into the experiment group
(medical synthetic treatments combined with Transmetil,
n = 32) and the control group (only medical synthetic
